Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination ...

The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with ...

Independent Testing Confirms Elevated Magnet and Heavy Rare Earth Presence at Graphite One ...

Graphite One Inc. (TSXV: GPH) (OTCQX: GPHOF) ("Graphite One", "G1" or the "Company") announced today that results from ...